Results 161 to 170 of about 89,278 (236)

Hallucinations in critically ill patients: understanding the unreal. [PDF]

Crit Care
Sonneville R.
europepmc   +1 more source

Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence. [PDF]

Addiction
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as a potential therapeutic target due to its pharmacological properties and mode of action in the endocannabinoid system.
Redonnet B, Eren F, Avenin G, Melchior M, Mary-Krause M.   +4 more
europepmc   +2 more sources

Hetrombopag: A promising thrombopoietin receptor agonist for the treatment of primary and secondary immune thrombocytopenia

Rheumatology &Autoimmunity, EarlyView.
This review seeks to provide a thorough synthesis of the existing literature on the role of thrombopoietin receptor agonists in the treatment of primary and secondary immune thrombocytopenia, with particular emphasis on the compound Hetrombopag. Abstract Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by a platelet count below
Jiaqi Hu, Zhida Fu, Xia Xu, Zhengyi Jin, Xinyu Qian, Weiyu Tao, Taiyan Ma, Dongbao Zhao, Jie Gao   +8 more
wiley   +1 more source

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report. [PDF]

Addict Sci Clin Pract
Azar P, Machado J, Kim JJ, Wong JSH, Nikoo M, Li VW.   +5 more
europepmc   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study. [PDF]

Reg Anesth Pain Med
Elyn A, Roussin A, Lestrade C, Franchitto N, Jullian B, Cantagrel N.   +5 more
europepmc   +1 more source

A Protein Corona‐Based Diagnostic Tool for Eroded Atherosclerotic Plaques

Small, EarlyView.
Protein Corona (PC) is a layer of proteins formed on the surface of nanoparticles (NPs) that are used as a tool for discriminati onof an experimental superficial erosion atherosclerotic injury in mice. Through a selection of different metals in the composition of metal‐organic framework (MOF) NPs, distinct corona proteins are formed on its surface, as ...
Santiago Alonso Tobar Leitão, Grasiele Sausen, Yuan Liu, Yanbao Yu, Antonietta Greco, Roberto Molinaro, Omid C. Farokhzad, Claudia Corbo, Peter Libby   +8 more
wiley   +1 more source

'Tranq': perceptions of xylazine and harm reduction practices among people receiving treatment for substance use disorders. [PDF]

Harm Reduct J
Salwan A, Dowling-McClay K, Greer D, AlAli A, Brooks B.   +4 more
europepmc   +1 more source

Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy

Small Science, EarlyView.
Autophagy modulation holds promise for enhancing cancer treatment, yet clinical translation remains challenging. This review explores nanomedicine‐based strategies to improve autophagy‐targeting drugs, highlighting their synergy with chemotherapy, immunotherapy, phototherapy, and gene therapy. It also discusses nanoparticle design and clinical progress,
Sohaib Mahri, Rodolfo Villa, Ya‐Ping Shiau, Menghuan Tang, Kelsey Jane Racacho, Qiufang Zong, Saiful Islam Chowdhury, Tan Hua, Felipe Godinez, Andrew Birkeland, Tzu‐Yin Lin, Yuanpei Li   +11 more
wiley   +1 more source

Addressing the needs of infants with prenatal substance exposure: implementation of CAPTA and CARA legislation in an urban hospital setting. [PDF]

Front Public Health
Jose A, Wetzler S, Kaplan JR, Mendoza A, Martin J, Mowrey W.   +5 more
europepmc   +1 more source